FDCDDQ
NVLN

Federation des caisses Desjardins du Quebec’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-40
Closed -$29 – 2404
2019
Q3 		$29 Hold
40
– – ﹤0.01% 2258
2019
Q2 		$31 Hold
40
– – ﹤0.01% 2241
2019
Q1 		$49 Hold
40
– – ﹤0.01% 2057
2018
Q4 		$34 Hold
40
– – ﹤0.01% 2060
2018
Q3 		$118 Hold
40
– – ﹤0.01% 2110
2018
Q2 		$147 Hold
40
– – ﹤0.01% 2127
2018
Q1 		$140 Hold
40
– – ﹤0.01% 2121
2017
Q4 		$125 Hold
40
– – ﹤0.01% 2106
2017
Q3 		$281 Hold
40
– – ﹤0.01% 2043
2017
Q2 		$369 Buy
+40
New +$385 ﹤0.01% 2099

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's NVLN Position: Q4 2019 in Review

Federation des caisses Desjardins du Quebec sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 40 shares — an estimated $29 sold.

Federation des caisses Desjardins du Quebec first reported a position in NVLN in Q2 2017 and held it in 10 quarters. The position peaked at $369 in Q2 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Federation des caisses Desjardins du Quebec reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 40 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $29.
  • Federation des caisses Desjardins du Quebec first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 10 quarters.
  • Federation des caisses Desjardins du Quebec's Novelion Therapeutics Inc. Common Shares position peaked at $369 in Q2 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2019, filed 30 Aug 2024.